Hassan Fazilaty

Group leader

University Hospital of Zurich
Country flagSwitzerland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (13)

Year:

2026

Single-cell profiling technologies allow exploring molecular mechanisms that drive development, health, and disease. However, current methods still fall short of profiling single cell transcriptomes comprehensively, with one major challenge being high non-detection rates of specific transcripts and transcript regions. Such information is often crucial to understanding the biology of cells. Here, we introduce RoCK and ROI (Robust Capture of Key transcripts and Regions Of Interest), a scRNA-seq workflow encompassing two techniques. RoCKseq uses targeted capture to enrich for key transcripts, thereby supporting the detection and identification of cell types and complex phenotypes in scRNA-seq experiments. ROIseq directs a subset of reads to a specific region of interest via selective priming. Importantly, RoCK and ROI enables retrieval of specific sequence information without compromising overall single cell transcriptome information. We validate RoCK and ROI across diverse biological systems highlighting the versatility and showing the power of the method to retrieve critical transcriptomic features.

Year:

2025

Year:

2025

It is estimated that only 0.02% of disseminated tumour cells are able to seed overt metastases 1 . While this suggests the presence of environmental constraints to metastatic seeding, the landscape of host factors controlling this process remains largely unclear. Here, combining transposon technology 2 and fluorescence niche labelling 3 , we developed an in vivo CRISPR activation screen to systematically investigate the interactions between hepatocytes and metastatic cells. We identify plexin B2 as a critical host-derived regulator of liver colonization in colorectal and pancreatic cancer and melanoma syngeneic mouse models. We dissect a mechanism through which plexin B2 interacts with class IV semaphorins on tumour cells, leading to KLF4 upregulation and thereby promoting the acquisition of epithelial traits. Our results highlight the essential role of signals from the liver parenchyma for the seeding of disseminated tumour cells before the establishment of a growth-promoting niche. Our findings further suggest that epithelialization is required for the adaptation of CRC metastases to their new tissue environment. Blocking the plexin-B2–semaphorin axis abolishes metastatic colonization of the liver and therefore represents a therapeutic strategy for the prevention of hepatic metastases. Finally, our screening approach, which evaluates host-derived extrinsic signals rather than tumour-intrinsic factors for their ability to promote metastatic seeding, is broadly applicable and lays a framework for the screening of environmental constraints to metastasis in other organs and cancer types.

Year:

2024

Year:

2024

Eosinophils, traditionally associated with allergic responses, have emerged as critical immune modulators in colorectal cancer (CRC). Here, we reveal that eosinophils actively shape the tumor microenvironment and influence metastatic progression. Using comprehensive transcriptomics analysis of human CRC and a murine orthotopic tumor model, we identify a conserved tumor-specific eosinophil signature and activation profile. Despite their declining presence in advanced CRC, eosinophils suppress metastatic dissemination by counteracting the pro-tumorigenic functions of SPP1 + macrophages – a subset linked to immune exclusion and tumor metastasis. Mechanistically, eosinophils respond to tumor-derived signals and inhibit macrophage differentiation into SPP1 + cells. Eosinophil depletion exacerbates peritoneal tumor spread. These findings highlight the pivotal role of eosinophils in restraining late-stage CRC progression and unveil a novel eosinophil–macrophage axis as potential therapeutic targets.

Year:

2024

Reactivated embryonic programs are associated with cancer progression, yet their role and regulatory mechanisms remain poorly understood. In this study, we introduce ‘oncoembryology,’ an approach that systematically compares embryonic and cancerous tissues to identify shared molecular programs and assess their functional relevance in disease. Applying this strategy to colorectal cancer, we identified SoxC transcription factors (Sox4, Sox11, Sox12) as critical regulators of both embryonic development and tumorigenesis. SoxC transcription factors regulate diverse downstream targets, including Tead2, Mdk, and Klf4, thereby regulating crucial steps of colon development. Abrogating SoxC function in murine models reduced tumor growth and prevented liver metastasis. Concordantly, a SoxC-driven oncoembryonic gene signature correlated with poor survival in colorectal cancer patients, underscoring the therapeutic potential of targeting SoxC-regulated pathways in cancer treatment.

Year:

2024

The immune composition of the tumor microenvironment (TME) has a major impact on the therapeutic response and clinical outcome in patients with colorectal cancer (CRC). Here, we comprehensively characterize the TME at the single-cell level by first building a large-scale atlas that integrates 4.27 million single cells from 1,670 patient samples. We then complemented the atlas with single-cell profiles from four CRC cohorts with 266 patients, including cells with low mRNA content, spatial transcriptional profiles from 3.7 million cells, and protein profiles from 0.7 million cells. The analysis of the atlas allows refined tumor classification into four immune phenotypes: immune desert, B cell enriched, T cell enriched, and myeloid cell enriched subtypes. Within the myeloid compartment we uncover distinct subpopulations of neutrophils that acquire new functional properties in blood and in the TME, including anti-tumorigenic capabilities. Further, spatial multimodal single-cell profiling reveals that neutrophils are organized in clusters within distinct functional niches. Finally, using an orthotopic mouse model we show that cancer-derived systemic signals modify neutrophil production in the bone marrow, providing evidence for tumor-induced granulopoiesis. Our study provides a big data resource for the CRC and suggests novel therapeutic strategies targeting neutrophils.

Year:

2024

Various tools have been developed to reliably identify, trace and analyze single cells in complex tissues. In recent years, these technologies have been combined with transcriptomic profiling approaches to explore molecular mechanisms that drive development, health, and disease. However, current methods still fall short of profiling single cell transcriptomes comprehensively, with one major challenge being high non-detection rates of specific transcripts and transcript regions. Such information is often crucial to understanding the biology of cells or tissues and includes lowly expressed transcripts, sequence variations and exon junctions. Here, we developed a scRNAseq workflow, RoCK and ROI (Robust Capture of Key transcripts and Regions Of Interest), that tackles these limitations. RoCKseq uses targeted capture to enrich for key transcripts, thereby supporting the detection and identification of cell types and complex phenotypes in scRNAseq experiments. ROIseq directs a subset of reads to a specific region of interest via selective priming to ensure detection. Importantly, RoCK and ROI guarantees efficient retrieval of specific sequence information without compromising overall single cell transcriptome information and our workflow is supported by a novel bioinformatics pipeline to analyze the multimodal information. RoCK and ROI represents a significant enhancement over non-targeted single cell sequencing, particularly when cell categorization depends on transcripts that are missed in standard scRNAseq experiments. In addition, it also allows exploration of biological questions that require assessment of specific sequence elements along the targets to be addressed.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (22)

Dietmar Rieder

Medical University of Innsbruck

AUSTRIA
View details

Stefan Salcher

Medical University of Innsbruck

AUSTRIA
View details

Maries van den Broek

Professor

University of Zurich

SWITZERLAND
View details

Isabelle C. Arnold

Assistant Professor

University of Zurich

SWITZERLAND
View details

Alexander Kirchmair

Medical University of Innsbruck

AUSTRIA
View details

Paul Ziegler

University Hospital Frankfurt

GERMANY
View details

Mark Robinson

Full Professor (of Statistical Genomics)

University of Zurich

SWITZERLAND
View details

Christian Münz

University of Zurich

SWITZERLAND
View details

Markus Tschurtschenthaler

Junior Group Leader

Technical University of Munich

GERMANY
View details

Andreas Moor

Assistant Professor (TT)

ETH Zürich

SWITZERLAND
View details

Konrad Basler

University of Zurich

SWITZERLAND
View details

Randall Platt

Associate Professor

ETH Zürich

SWITZERLAND
View details

Andreas Seeber

Medical University of Innsbruck

AUSTRIA
View details

Andreas Pircher

PD Dr

Medical University of Innsbruck

AUSTRIA
View details

Noel de Miranda

Professor

Leiden University Medical Center

NETHERLANDS
View details

Steffen Ormanns

Medical University of Innsbruck

AUSTRIA
View details

Zlatko Trajanoski

Professor

Medical University of Innsbruck

AUSTRIA
View details

Hariharan Easwaran

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Jose P Lopez-Atalaya

Principal Investigator

Consejo Superior de Investigaciones Cientificas

SPAIN
View details

patrizia stoitzner

Professor for Experimental Dermatology

Medical University of Innsbruck

AUSTRIA
View details

Marieke Ijsselsteijn

Leiden University Medical Center

NETHERLANDS
View details

Salvatore Piscuoglio

Associate Professor

Humanitas University

ITALY
View details